370 related articles for article (PubMed ID: 31961981)
21. The μ-opioid receptor and treatment response to naltrexone.
Thorsell A
Alcohol Alcohol; 2013; 48(4):402-8. PubMed ID: 23543091
[TBL] [Abstract][Full Text] [Related]
22. Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis.
Chamorro AJ; Marcos M; Mirón-Canelo JA; Pastor I; González-Sarmiento R; Laso FJ
Addict Biol; 2012 May; 17(3):505-12. PubMed ID: 22515274
[TBL] [Abstract][Full Text] [Related]
23. Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment.
Tidey JW; Monti PM; Rohsenow DJ; Gwaltney CJ; Miranda R; McGeary JE; MacKillop J; Swift RM; Abrams DB; Shiffman S; Paty JA
Alcohol Clin Exp Res; 2008 Jan; 32(1):58-66. PubMed ID: 18028530
[TBL] [Abstract][Full Text] [Related]
24. A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients.
Kim SG; Kim CM; Choi SW; Jae YM; Lee HG; Son BK; Kim JG; Choi YS; Kim HO; Kim SY; Oslin DW
Psychopharmacology (Berl); 2009 Jan; 201(4):611-8. PubMed ID: 18795264
[TBL] [Abstract][Full Text] [Related]
25. Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers.
Arias AJ; Armeli S; Gelernter J; Covault J; Kallio A; Karhuvaara S; Koivisto T; Mäkelä R; Kranzler HR
Alcohol Clin Exp Res; 2008 Jul; 32(7):1159-66. PubMed ID: 18537939
[TBL] [Abstract][Full Text] [Related]
26. Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence.
Garbutt JC; Greenblatt AM; West SL; Morgan LC; Kampov-Polevoy A; Jordan HS; Bobashev GV
Addiction; 2014 Aug; 109(8):1274-84. PubMed ID: 24661324
[TBL] [Abstract][Full Text] [Related]
27. Pharmacogenetic Effects of Naltrexone in Individuals of East Asian Descent: Human Laboratory Findings from a Randomized Trial.
Ray LA; Green R; Roche DJO; Bujarski S; Hartwell EE; Lim AC; Rohrbaugh T; Ghahremani D; Hutchison K; Miotto K
Alcohol Clin Exp Res; 2018 Mar; 42(3):613-623. PubMed ID: 29265379
[TBL] [Abstract][Full Text] [Related]
28. Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype.
Ziauddeen H; Nestor LJ; Subramaniam N; Dodds C; Nathan PJ; Miller SR; Sarai BK; Maltby K; Fernando D; Warren L; Hosking LK; Waterworth D; Korzeniowska A; Win B; Richards DB; Vasist Johnson L; Fletcher PC; Bullmore ET
Neuropsychopharmacology; 2016 Oct; 41(11):2647-57. PubMed ID: 27109624
[TBL] [Abstract][Full Text] [Related]
29. OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence.
Coller JK; Cahill S; Edmonds C; Farquharson AL; Longo M; Minniti R; Sullivan T; Somogyi AA; White JM
Pharmacogenet Genomics; 2011 Dec; 21(12):902-5. PubMed ID: 21946895
[TBL] [Abstract][Full Text] [Related]
30. Genetic moderators of naltrexone's effects on alcohol cue reactivity.
McGeary JE; Monti PM; Rohsenow DJ; Tidey J; Swift R; Miranda R
Alcohol Clin Exp Res; 2006 Aug; 30(8):1288-96. PubMed ID: 16899031
[TBL] [Abstract][Full Text] [Related]
31. Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status.
Schacht JP; Randall PK; Latham PK; Voronin KE; Book SW; Myrick H; Anton RF
Neuropsychopharmacology; 2017 Dec; 42(13):2640-2653. PubMed ID: 28409564
[TBL] [Abstract][Full Text] [Related]
32. Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone.
Setiawan E; Pihl RO; Benkelfat C; Leyton M
Pharmacogenomics; 2012 Jul; 13(10):1161-72. PubMed ID: 22909206
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial.
Schacht JP; Hoffman M; Chen BH; Anton RF
Pharmacogenomics J; 2022 Feb; 22(1):1-8. PubMed ID: 34381173
[TBL] [Abstract][Full Text] [Related]
34. The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review.
Ray LA; Barr CS; Blendy JA; Oslin D; Goldman D; Anton RF
Alcohol Clin Exp Res; 2012 Mar; 36(3):385-94. PubMed ID: 21895723
[TBL] [Abstract][Full Text] [Related]
35. A pharmacogenetic model of naltrexone-induced attenuation of alcohol consumption in rhesus monkeys.
Vallender EJ; Rüedi-Bettschen D; Miller GM; Platt DM
Drug Alcohol Depend; 2010 Jun; 109(1-3):252-6. PubMed ID: 20153935
[TBL] [Abstract][Full Text] [Related]
36. OPRM1 Moderates Daily Associations of Naltrexone Adherence With Alcohol Consumption: Preliminary Evidence From a Mobile Health Trial.
Hendershot CS; Dermody SS; Wardell JD; Zaso MJ; Kennedy JL; Stoner SA
Alcohol Clin Exp Res; 2020 Apr; 44(4):983-991. PubMed ID: 32020635
[TBL] [Abstract][Full Text] [Related]
37. Alcohol Consumption in Healthy OPRM1 G Allele Carriers and Its Association with Impulsive Behavior.
Pfeifer P; Sariyar M; Eggermann T; Zerres K; Vernaleken I; Tüscher O; Fehr C
Alcohol Alcohol; 2015 Jul; 50(4):379-84. PubMed ID: 25836994
[TBL] [Abstract][Full Text] [Related]
38. Influence of the A118G Polymorphism of the OPRM1 Gene and Exon 3 VNTR Polymorphism of the DRD4 Gene on Cigarette Craving After Alcohol Administration.
Lechner WV; Knopik VS; McGeary JE; Spillane NS; Tidey JW; McKee SA; Metrik J; Leventhal AM; Rohsenow DJ; Kahler CW
Nicotine Tob Res; 2016 May; 18(5):632-6. PubMed ID: 26092968
[TBL] [Abstract][Full Text] [Related]
39. The Asp40 mu-opioid receptor allele does not predict naltrexone treatment efficacy in heavy drinkers.
Mitchell JM; Fields HL; White RL; Meadoff TM; Joslyn G; Rowbotham MC
J Clin Psychopharmacol; 2007 Feb; 27(1):112-5. PubMed ID: 17224736
[No Abstract] [Full Text] [Related]
40. Polymorphisms of the mu-opioid receptor and dopamine D4 receptor genes and subjective responses to alcohol in the natural environment.
Ray LA; Miranda R; Tidey JW; McGeary JE; MacKillop J; Gwaltney CJ; Rohsenow DJ; Swift RM; Monti PM
J Abnorm Psychol; 2010 Feb; 119(1):115-25. PubMed ID: 20141248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
